Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XON7 in Advanced or Metastatic Solid Tumors
NCT06154291Phase 2Recruiting
- Sponsor
- Xenothera
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of X0N7 in solid tumor, sponsored by Xenothera. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment Emergent Adverse Events at 60 days and 4 more. Started Nov 2023; status: recruiting.
02
Drugs
X0N7
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06154291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06154291.